369 related articles for article (PubMed ID: 20231127)
1. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.
Cárdenes HR; Price TR; Perkins SM; Maluccio M; Kwo P; Breen TE; Henderson MA; Schefter TE; Tudor K; Deluca J; Johnstone PA
Clin Transl Oncol; 2010 Mar; 12(3):218-25. PubMed ID: 20231127
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
Kim JW; Seong J; Lee IJ; Woo JY; Han KH
Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
[TBL] [Abstract][Full Text] [Related]
5. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
[TBL] [Abstract][Full Text] [Related]
7. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
Gkika E; Schultheiss M; Bettinger D; Maruschke L; Neeff HP; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Radiat Oncol; 2017 Jul; 12(1):116. PubMed ID: 28701219
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.
Méndez Romero A; Wunderink W; Hussain SM; De Pooter JA; Heijmen BJ; Nowak PC; Nuyttens JJ; Brandwijk RP; Verhoef C; Ijzermans JN; Levendag PC
Acta Oncol; 2006; 45(7):831-7. PubMed ID: 16982547
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
Sanuki N; Takeda A; Oku Y; Mizuno T; Aoki Y; Eriguchi T; Iwabuchi S; Kunieda E
Acta Oncol; 2014 Mar; 53(3):399-404. PubMed ID: 23962244
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
11. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy.
Lasley FD; Mannina EM; Johnson CS; Perkins SM; Althouse S; Maluccio M; Kwo P; Cárdenes H
Pract Radiat Oncol; 2015; 5(5):e443-e449. PubMed ID: 25899219
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities.
Lazarev S; Hardy-Abeloos C; Factor O; Rosenzweig K; Buckstein M
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2077-2083. PubMed ID: 30088143
[TBL] [Abstract][Full Text] [Related]
13. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
14. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
Rusthoven KE; Kavanagh BD; Cardenes H; Stieber VW; Burri SH; Feigenberg SJ; Chidel MA; Pugh TJ; Franklin W; Kane M; Gaspar LE; Schefter TE
J Clin Oncol; 2009 Apr; 27(10):1572-8. PubMed ID: 19255321
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
[TBL] [Abstract][Full Text] [Related]
16. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
Eriguchi T; Takeda A; Sanuki N; Oku Y; Aoki Y; Shigematsu N; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1006-11. PubMed ID: 23102838
[TBL] [Abstract][Full Text] [Related]
17. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.
Bujold A; Massey CA; Kim JJ; Brierley J; Cho C; Wong RK; Dinniwell RE; Kassam Z; Ringash J; Cummings B; Sykes J; Sherman M; Knox JJ; Dawson LA
J Clin Oncol; 2013 May; 31(13):1631-9. PubMed ID: 23547075
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
Son SH; Choi BO; Ryu MR; Kang YN; Jang JS; Bae SH; Yoon SK; Choi IB; Kang KM; Jang HS
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1073-80. PubMed ID: 20207492
[TBL] [Abstract][Full Text] [Related]
19. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
[TBL] [Abstract][Full Text] [Related]
20. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
